A5021949390- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Neuroblastoma Research and Treatments
- Prostate Cancer Treatment and Research
- Receptor Mechanisms and Signaling
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Radiopharmaceutical Chemistry and Applications
Amgen (United States)
2022-2024
5012 Background: NEPC is an aggressive form of prostate cancer with poor prognosis and no standard treatment approach. can be characterized by late, treatment-emergent transformation from adenocarcinoma to high-grade neuroendocrine carcinoma (NEC), in 10–15% mCRPC patients (pts). DLL3 overexpressed NECs, including NEPC, minimally expressed on normal tissue. Tarlatamab, a bispecific T-cell engager immunotherapy clinical activity small cell lung (SCLC), binds CD3 resulting mediated tumor...
Abstract Effective treatments for de novo and treatment-emergent small-cell/neuroendocrine (t-SCNC) prostate cancer represent an unmet need this disease. Using metastatic biopsies from patients with advanced cancer, we demonstrate that delta-like ligand 3 (DLL3) is expressed in t-SCNC associated reduced survival. We develop a PET agent, [89Zr]-DFO-DLL3-scFv, detects DLL3 levels mouse SCNC models. In multiple patient-derived xenograft models, AMG 757 (tarlatamab), half-life–extended...
<p>Supplementary Data: Figures and Legends combined</p>
<p>Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of (labeled with NuclightRed) co-cultured T either NT control BiTE® or AMG 757. were plated at an E:T ratio 5:1. Images captured every 6 hours 10x magnification. a. treated BiTE®. b. c. d. 757.</p>
<p>Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) SHP-77 NuclightRed) co-cultured T cells. Both the were plated at equal densities treated either NT control BiTE®, AMG 757, or PSMA-targeting HLE BiTE, 160. added to each well an E:T ratio 10:1. Images captured every 4 hours 4x magnification for 5 days. a. 22Rv1, SHP-77, BiTE®. b. 757. c. 160.</p>
<p>FigureS8</p>
<p>FigureS5</p>
<p>FigureS10</p>
<p>FigureS6</p>
<p>FigureS9</p>
<p>FigureS8</p>
<p>FigureS6</p>
<p>FigureS5</p>
<p>FigureS7</p>
<p>FigureS2</p>
<p>FigureS1</p>
<p>FigureS3</p>
<p>FigureS10</p>
<p>FigureS3</p>
<p>FigureS2</p>
<div>Abstract<p>Effective treatments for <i>de novo</i> and treatment-emergent small-cell/neuroendocrine (t-SCNC) prostate cancer represent an unmet need this disease. Using metastatic biopsies from patients with advanced cancer, we demonstrate that delta-like ligand 3 (DLL3) is expressed in t-SCNC associated reduced survival. We develop a PET agent, [<sup>89</sup>Zr]-DFO-DLL3-scFv, detects DLL3 levels mouse SCNC models. In multiple patient-derived...
<p>Supplementary Data: Figures and Legends combined</p>
<p>Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of (labeled with NuclightRed) co-cultured T either NT control BiTE® or AMG 757. were plated at an E:T ratio 5:1. Images captured every 6 hours 10x magnification. a. treated BiTE®. b. c. d. 757.</p>
<p>Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of (labeled with NuclightRed) co-cultured T either NT control BiTE® or AMG 757. were plated at an E:T ratio 5:1. Images captured every 6 hours 10x magnification. a. treated BiTE®. b. c. d. 757.</p>